Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Anand A. Dalal
Patrick Gagnon-Sanschagrin
Rebecca Burne
Annie Guérin
Geneviève Gauthier
Tania Small
Polly Niravath
机构：
[1] Novartis Pharmaceuticals Corporation,
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Dose modification; Drug wastage; Economic burden; HR+/HER2− metastatic breast cancer; Oncology; Palbociclib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：768 / 778
页数：10
相关论文
共 50 条
  • [21] Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2− Metastatic Breast Cancer
    Annie Guérin
    Debbie Goldschmidt
    Tania Small
    Patrick Gagnon-Sanschagrin
    Hela Romdhani
    Genevieve Gauthier
    Sneha Kelkar
    Eric Q. Wu
    Polly Niravath
    Anand A. Dalal
    Advances in Therapy, 2018, 35 : 1251 - 1264
  • [22] Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2-Metastatic Breast Cancer
    Brufsky, Adam M.
    Sandin, Rickard
    Stergiopoulos, Stella
    Chen, Connie
    Karanth, Siddharth
    Li, Benjamin
    Esterberg, Elizabeth
    Makari, Doris
    Candrilli, Sean D.
    Goyal, Ravi K.
    Rugo, Hope S.
    CANCER MEDICINE, 2025, 14 (07):
  • [23] Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice
    Angela DeMichele
    Massimo Cristofanilli
    Adam Brufsky
    Xianchen Liu
    Jack Mardekian
    Lynn McRoy
    Rachel M. Layman
    Birol Emir
    Mylin A. Torres
    Hope S. Rugo
    Richard S. Finn
    Breast Cancer Research, 23
  • [24] Controversial topics in metastatic HR+/HER2-breast cancer: Guiding treatment by a modified Delphi approach
    Fabi, Alessandra
    Buono, Giuseppe
    Bria, Emilio
    Bianchini, Giampaolo
    Curigliano, Giuseppe
    De Laurentiis, Michelino
    De Placido, Sabino
    Del Mastro, Lucia
    Guarneri, Valentina
    Generali, Daniele
    Livi, Lorenzo
    Lorusso, Vito
    Montemurro, Filippo
    Puglisi, Fabio
    Vigneri, Paolo
    Zambelli, Alberto
    Arpino, Grazia
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Real-World Palbociclib Use in HR+/HER2-Advanced Breast Cancer in Canada: The IRIS Study
    Mycock, Katie
    Zhan, Lin
    Taylor-Stokes, Gavin
    Milligan, Gary
    Mitra, Debanjali
    CURRENT ONCOLOGY, 2021, 28 (01) : 678 - 688
  • [26] Palbociclib in a patient with HR+/HER2- advanced breast cancer and HIV1 infection: a case report
    Canino, Fabio
    Moscetti, Luca
    Borghi, Vanni
    Dominici, Massimo
    Piacentini, Federico
    BREAST CANCER MANAGEMENT, 2021, 10 (04)
  • [27] Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2-advanced breast cancer
    Tremblay, Gabriel
    Chandiwana, David
    Dolph, Mike
    Hearnden, Jaclyn
    Forsythe, Anna
    Monaco, Mauricio
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1319 - 1327
  • [28] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
    Porte, B.
    Carton, M.
    Lerebours, F.
    Brain, E.
    Loirat, D.
    Haroun, L.
    Bellesoeur, A.
    Hamba, S. Bach
    Kirova, Y.
    Cottu, P.
    BREAST, 2020, 54 : 303 - 310
  • [29] Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
    Engel-Nitz, Nicole M.
    Johnson, Mary G.
    Johnson, Michael P.
    Cha-Silva, Ashley S.
    Kurosky, Samantha K.
    Liu, Xianchen
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 1049 - 1062
  • [30] Current Treatment Patterns Among Postmenopausal Women with HR+/HER2-Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study
    Goldschmidt, Deborah
    Dalal, Anand A.
    Romdhani, Hela
    Kelkar, Sneha
    Guerin, Annie
    Gauthier, Genevieve
    Wu, Eric Q.
    Niravath, Polly
    Small, Tania
    ADVANCES IN THERAPY, 2018, 35 (04) : 482 - 493
12345